How have the shares performed?
ImmunityBio Inc. (IBRX) saw an uptrend of 4.76% in the recent trading with $16.49 being its most recent. The current price level -63.69% lower than the highest price of $45.42 marked by the stock while trading over the past 52-weeks, whereas it is 223.33% higher than the lowest price of $5.10 the company dropped to over past 52-weeks. The latest news story on IBRX appeared in Business Wire under the title “ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a Universal Boost in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa” on May-25-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -16.38% below one month high and is +17.79% above of the lowest during that time. Looking into the simple moving average, ImmunityBio Inc. (IBRX)’s stock stands at a SMA-50 of $20.23 while that of 5-day is reading $16.17.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and IBRX’s SMA-200 as of now is $15.74.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.
ImmunityBio Inc. Earnings – What Happened With IBRX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. ImmunityBio Inc. (IBRX) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of 48.80% for net revenue.
IBRX – ImmunityBio Inc. Stock Earnings Estimates
The perspective of ImmunityBio Inc. (NASDAQ:IBRX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.41 for stock’s EPS in the current quarter. 1 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.21.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 382.74 million. IBRX does have institutional investors; and they hold 4.30% of the stock.
ImmunityBio Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 1 new insider purchases involving 56,967 shares. On the other hand, IBRX declared 448,498 shares have been sold in 9 insider transactions over the past three months.
Currently, the stock has been recommended as Moderate Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.
Technical Analysis of ImmunityBio Inc. (NASDAQ:IBRX) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for ImmunityBio Inc. (IBRX), we notice that the stock’s 20-day average volume is at 1,289,180 shares. Its 50-day average volume of 1,276,978 shares. And to end with, IBRX’s 100-day average volume are 1,397,913 shares.